XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure

DENTSPLY SIRONA (XRAY) exceeded Q2 earnings and revenue estimates with adjusted EPS of 52 cents versus 36 cents consensus, though revenues fell 4.1% year-over-year. The company maintained full-year 2026 guidance of $3.5-3.6B in sales and $1.40-1.50 adjusted EPS. Wellspect Healthcare grew 7.1%, but three dental segments declined, with tariff pressures and lower volumes constraining operating margins. Free cash flow improved to $55M from $16M year-ago.